Optimizing antithrombotic therapy after coronary stent implantation in patients on chronic oral anticoagulation

Area of Science:

• Cardiology
• Pharmacology
• Clinical Medicine

Background:

• Patients on chronic oral anticoagulation often require dual antiplatelet therapy (aspirin and P2Y12 inhibitor) after percutaneous coronary interventions with stent implantation.
• This combination, known as triple therapy, significantly increases bleeding risks, which is linked to higher mortality rates.
• Newer, potent antiplatelet agents further elevate bleeding concerns, creating a complex clinical dilemma.

Purpose of the Study:

• To review current evidence on managing patients requiring both oral anticoagulation and dual antiplatelet therapy after stenting.
• To explore optimal antithrombotic strategies that mitigate bleeding risks while maintaining efficacy.

Main Methods:

• Systematic review of clinical trials and observational studies.
• Analysis of data concerning bleeding events and thrombotic outcomes.
• Evaluation of different antithrombotic regimens.

Main Results:

• Triple therapy is associated with a substantial increase in bleeding complications.
• The choice of oral anticoagulant and antiplatelet agent impacts bleeding risk.
• Ongoing trials are investigating shorter durations or de-escalated regimens.

Conclusions:

• Optimal management requires careful consideration of individual patient risk factors for both thrombosis and bleeding.
• Balancing the benefits of dual antiplatelet therapy with oral anticoagulation against bleeding risks is crucial.
• Further research is needed to establish definitive guidelines for this high-risk patient population.